Bone biologics regains compliance with nasdaq continued listing requirements

Burlington, mass.--(business wire)--bone biologics corporation (“bone biologics” or the “company”) (nasdaq: bblg, bblgw), a developer of orthobiologic products for spine fusion markets, today announced that it has received notice from the nasdaq stock market llc (nasdaq) informing the company that it has regained compliance with the minimum bid price requirement under nasdaq listing rule 5550(a)(2) for continued listing on the nasdaq capital market. bone biologics is now in compliance with all.
BBLG Ratings Summary
BBLG Quant Ranking